Namrata S. Patil

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (5)

• Automated tumor immunophenotyping predicts clinical benefit from anti‐PD‐L1 immunotherapy
  The Journal of Pathology 2024 DOI: 10.1002/path.6274
  +Save
• Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
  Nature 2024 DOI: 10.1038/s41586-024-07121-9
  +Save
• Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
  Cancer Cell 2022 DOI: 10.1016/j.ccell.2022.02.002
  +Save
• ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
  JCO Precision Oncology 2021 DOI: 10.1200/PO.21.00057
  +Save
• C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
  PLOS ONE 2021 DOI: 10.1371/journal.pone.0246486
  +Save